Fungal compound compositions and methods for modulating inflammation

Described herein are fungal compound compositions and methods for treating, prophylaxis of, or ameliorating symptoms of one or more adverse reactions triggered by an infectious disease or condition that increases an anti-inflammatory response in a subject with such compositions. In one aspect, the composition comprises one or more tryptamines or in pure form or extracts from psilocybin containing mushrooms, or combinations thereof, optionally combined with one or more erinacines or hericenones in pure form, extracts from Hericium mushroom species (e.g., H. erinaceus, H. coralloides, H. ramosum), or combinations thereof, optionally one or more adversive compounds, optionally one or more monoamine oxidase inhibitor (MAOI) compounds, and optionally one or more pharmaceutically acceptable excipients.

Psilocybin and psilocin conjugates for treatment of mental illnesses

New psilocybin and psilocin conjugates and their soluble salts with synergistic or additive therapeutic agents and stable formulations thereof, as well as their medical applications. The synergistic or additive conjugates may be used as drugs or prodrugs for treating various mental illness conditions related to the modulation or biased modulation of serotonin and related receptors, including but not limited to neurodegenerative disorders, depression, anxiety, obsessive compulsive disorder (OCD), cluster headaches, neuropathic pain and addiction.

Hallucinogen-fatty acid combination

The present application relates to combination compositions comprising one or more hallucinogens, or a pharmaceutically acceptable salt, prodrug and/or solvate thereof, and one or more fatty acids, or a pharmaceutically acceptable salt, prodrug and/or solvate thereof. The present application also relates to intranasal pharmaceutical compositions comprising one or more hallucinogens, or a pharmaceutically acceptable salt, prodrug and/or solvate thereof, and one or more fatty acids, or a pharmaceutically acceptable salt, prodrug and/or solvate thereof. For example, the one or more hallucinogens is 5-methoxy-N,N-dimethyltryptamine or a pharmaceutically acceptable salt thereof and the one or more fatty acids is linoleic acid.

Crystalline forms of psilacetin

Crystalline forms of 4-acetoxy-N,N-dimethyltryptamine (psilacetin), compositions containing that crystalline form, and their methods of use are disclosed. The crystalline forms of 4-acetoxy-N,N-dimethyltryptamine (psilacetin) according to the disclosure include crystalline 4-acetoxy-N,N-dimethyltryptammonium hydrofumarate, the fumarate salt of psilacetin, and/or crystalline bis(4-acetoxy-N,N-dimethyltryptammonium) fumarate, and pharmaceutical compositions containing a crystalline form of psilacetin.

Methods and compositions comprising psychoactive compounds from psychoactive organisms

This invention relates to the extraction of psychoactive compounds from organisms for use in medicine. Extraction is carried out with a strong acid or strong base to either promote or inhibit dephosphorylation. The extract in the slurry form is standardized with added excipient so that when it is dried the powdered composition has a specified total psychoactive alkaloid concentration, with a known ratio of phosphorylated to dephosphorylated psychoactive alkaloids.

Methods for producing tryptamine derivatives

The present disclosure relates to a method for producing a tryptamine derivative of formula (I), wherein the tryptamine derivative (I) is not tryptophan, 4-hydroxytryptamine, N-acetyl-4-hydroxytryptamine, norbaeocystin, baeocystin; psilocybin, psilocin, aeruginascin, halogenated tryptophan, halogenated tryptamine, halogenated N-methylated tryptamine, halogenated N,N-dimethyltryptamine or halogenated Ν,Ν,Ν-trimethyltryptamine; said method comprising providing an indole acceptor of the formula (II), wherein the tryptamine derivative (I) is not tryptophan, 4-hydroxytryptamine, N-acetyl-4-hydroxytryptamine, norbaeocystin, baeocystin; psilocybin, psilocin, aeruginascin, halogenated tryptophan, halogenated tryptamine, halogenated N-methylated tryptamine, halogenated N,N- dimethyltryptamine or halogenated Ν,Ν,Ν-trimethyltryptamine; said method comprising providing an indole acceptor of the formula (II), wherein one or more of Rll, RIV, RV, RVI or RVII is not H and Rill is H or CH2CH2NH2 or CH2CHCOOHNH2; and contacting the indole acceptor with a substituent donor in the precense of one or more enzymes substituting one or more H, OH and/or COOH in the indole acceptor with one or more substituents of the substituent donor.

Crystalline salts of psilocin

Crystalline salts of psilocin are disclosed. The beneficial and therapeutic uses of the crystalline psilocin salts and of compositions containing the crystalline psilocin salts are also disclosed. The disclosure sets out methods of making and characterizing the crystalline psilocin salts.

Heterocyclic compounds and methods of preparation thereof

This disclosure relates to heterocyclic compounds of Formula (I), Formula (II), and Formula (III) as well as the preparation and use thereof. As contemplated herein, heterocyclic compounds of Formula (I), Formula (II), and Formula (III) may be used for the treatment of neuropsychiatric, and neurodegenerative, neuroinflammatory and pain disorders including depression, as well as tobacco, opiate, and cocaine addiction, alcoholism, post-traumatic stress disorder (PTSD), and neuropathic pain syndromes including cluster headaches and chemotherapy induced peripheral neuropathy. Formula (I), Formula (II), Formula (III)

Crystalline salts of psilocin

Crystalline salts of psilocin are disclosed. The beneficial and therapeutic uses of the crystalline psilocin salts and of compositions containing the crystalline psilocin salts are also disclosed. The disclosure sets out methods of making and characterizing the crystalline psilocin salts.

Methods for the production of psilocybin and intermediates or side products

Provided are methods, prokaryotic host cells, expression vectors, and kits for the production of psilocybin or an intermediate or a side product thereof. Also provided are methods, prokaryotic host cells, expression vectors, and kits for the production of norbaeocystin. In certain embodiments, the prokaryotic host cell is selected from the group consisting of Escherichia coli, Corynebacterium glutamicum, Vibrio natriegens, Bacillus subtilis, Bacillus megaterium, Escherichia coli Nissle 1917, Clostridium acetobutlyicum, Streptomyces coelicolor, Lactococcus lactis, Pseudomonas putida, Streptomyces clavuligerus, and Streptomyces venezuelae.

>